1489 W. Warm Springs Road
Suite 110
Henderson, NV 89014
United States
702-757-6133
https://zurabio.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 14
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Verender S. Badial | Chief Financial Officer | 374,92k | S.O. | 1973 |
Dr. Michael D. Howell Ph.D. | Chief Scientific Officer & Head of Translational Medicine | 1,97M | S.O. | 1977 |
Ms. Kimberly Ann Davis | Chief Legal Officer & Secretary | 2,16M | S.O. | 1968 |
Mr. Robert Lisicki | President, CEO & Director | S.O. | S.O. | 1968 |
Dr. Gary Whale Ph.D. | Chief Technology Officer | S.O. | S.O. | 1974 |
Ms. Theresa Lowry | Chief Human Resources Officer | S.O. | S.O. | 1974 |
Mr. David Brady | Head of Business Development | 125,05k | S.O. | S.O. |
Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer & Head of Development | S.O. | S.O. | 1973 |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
L’ISS Governance QualityScore de Zura Bio Limited en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..